| Description | Enprofylline (Enprofilina), a bronchodilator, acts primarily as a competitive nonselective phosphodiesterase inhibitor. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of sickle cell disease, diabetic neuropathy, and cerebrovascular insufficiency. |
| Target activity | A2B receptor:7 μM (Ki) |
| Synonyms | Enprofilina, 3-propylxanthine, 3-n-Propylxanthine, Enprofyllinum, 恩丙茶碱 |
| molecular weight | 194.19 |
| Molecular formula | C8H10N4O2 |
| CAS | 41078-02-8 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | H2O: Insoluble DMSO: 60 mg/ml (308.98 mM) |
| References | 1. Mojsilovic-Petrovic J, Arneja A, Kalb RG. Enprofylline protects motor neurons from in vitro excitotoxic challenge. Neurodegener Dis. 2005;2(3-4):160-5. 2. Feoktistov I, Biaggioni I. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. J Clin Invest. 1995 Oct;96(4):1979-86. PubMed PMID: 7560091; PubMed Central PMCID: PMC185836. 3. Chapman KR, Ljungholm K, Kallen A. Long-term xanthine therapy of asthma. Enprofylline and theophylline compared. International Enprofylline Study Group. Chest. 1994 Nov;106(5):1407-1PubMed PMID: 7956392. 4. Nadai M, Hasegawa T, Wang L, Tagaya O, Nabeshima T. Alterations in the pharmacokinetics and protein binding of enprofylline in Eisai hyperbilirubinemic rats. Drug Metab Dispos. 1994 Jul-Aug;22(4):561-PubMed PMID: 7956730. |